Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Suzhou's PegBio Forms China Diabetes Partnership with Pfizer

publication date: Dec 15, 2016
PegBio Company, a Suzhou diabetes-focused pharma, partnered with Pfizer to bring a Pfizer clinical-stage type 2 diabetes treatment to China. The candidate seems to be PF-04937319, a glucokinase inhibitor that Pfizer designed to be only partially effective as a way of avoiding the hypoglycemic side effect of other GCK drugs. PF-04937319 has completed a Phase IIa trial in the US. Neither company has issued a press release offering details about the deal, though PegBio did affirm that an agreement had been signed. More details....

Stock Symbol: (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital